CIK: 0001055951
Total reported value
$5.0B
Reporting period: 2026-03-31 · Number of holdings: 114
ORBIMED ADVISORS LLC disclosed 114 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $5.0B and a quarterly turnover rate of 64.3%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "O"
Orbimed Advisors LLC's disclosed holdings carry a Herfindahl concentration index of 0.030 — mathematically equivalent to about 33 equally-sized positions, well below its 114 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.52), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 28% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Terms of Use for AI
AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/13f/orbimed-advisors-llc
Add ELVN
0.0% $189.4M
Trim LLY
-21.4% -$105.9M
Trim UPB
0.0% -$103.3M
Add EWTX
0.0% $103.7M
Trim BSX
-1.5% -$81.2M
Trim ALNY
-58.8% -$75.5M
Showing top 110 holdings (of 114 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics INC | Stock-Other | 10.02% | +1.83% | — | |
| 2 | ELVN | Enliven Therapeutics INC | Stock-Other | 6.39% | +3.68% | — | |
| 3 | ✓ | Mdxhealth SA | Stock-Other | 5.86% | +5.67% | NEW | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.46% | -2.29% | -21.38% | |
| 5 | RCEL | Avita Medical INC | Stock-Other | 4.04% | +3.90% | NEW | |
| 6 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.06% | -1.75% | -1.54% | |
| 7 | SION | Sionna Therapeutics INC | Stock-Other | 2.90% | — | -0.87% | |
| 8 | AZN | AstraZeneca PLC | Stock-Healthcare | 2.71% | +2.62% | NEW | |
| 9 | MYGN | Myriad Genetics INC | Stock-Other | 2.52% | +2.44% | NEW | |
| 10 | MBX | Mbx Biosciences INC | Stock-Other | 2.23% | -0.38% | -7.56% | |
| 11 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 2.15% | +0.95% | — | |
| 12 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.05% | -0.53% | -6.23% | |
| 13 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.02% | -1.52% | -38.25% | |
| 14 | ISRG | Intuitive Surgical INC | Stock-Healthcare | 1.97% | -1.13% | -20.77% | |
| 15 | CMPX | Compass Therapeutics INC | Stock-Other | 1.65% | — | — | |
| 16 | MRK | Merck & Co. INC. | Stock-Healthcare | 1.64% | +1.58% | NEW | |
| 17 | GPCR | Structure Therapeutics INC | Stock-Other | 1.46% | — | +26.99% | |
| 18 | AVBP | Arrivent Biopharma INC | Stock-Other | 1.43% | — | — | |
| 19 | IRON | Disc Medicine INC | Stock-Other | 1.40% | -0.38% | — | |
| 20 | SPRY | Ars Pharmaceuticals INC | Stock-Other | 1.36% | -0.65% | — | |
| 21 | CGON | Cg Oncology INC | Stock-Other | 1.32% | — | -37.47% | |
| 22 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 1.26% | +0.81% | +137.02% | |
| 23 | SYK | Stryker CORP | Stock-Healthcare | 1.23% | -1.14% | -43.85% | |
| 24 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.15% | — | +19.35% | |
| 25 | MLYS | Mineralys Therapeutics INC | Stock-Other | 1.14% | +0.37% | +109.39% | |
| 26 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.14% | +0.53% | +82.54% | |
| 27 | PFE | Pfizer INC | Stock-Healthcare | 1.12% | — | +17.76% | |
| 28 | DYN | Dyne Therapeutics INC | Stock-Other | 1.08% | — | +32.50% | |
| 29 | NTRA | Natera INC | Stock-Healthcare | 1.07% | -0.67% | -28.38% | |
| 30 | ABVX | Abivax Sa-adr | Stock-Other | 1.06% | — | +26.58% | |
| 31 | UPB | Upstream Bio INC | Stock-Other | 1.05% | -2.14% | — | |
| 32 | DHR | Danaher CORP | Stock-Healthcare | 1.03% | -0.40% | -11.34% | |
| 33 | CAI | Caris Life Sciences INC | Stock-Other | 1.03% | -0.73% | -9.92% | |
| 34 | ASND | Ascendis Pharma A/S | Stock-Other | 0.85% | — | +5.81% | |
| 35 | STTK | Shattuck Labs INC | Stock-Other | 0.83% | +0.33% | — | |
| 36 | GH | Guardant Health INC | Stock-Healthcare | 0.82% | +0.80% | NEW | |
| 37 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 0.81% | -1.56% | -58.80% | |
| 38 | PRLD | Prelude Therapeutics INC | Stock-Other | 0.76% | — | — | |
| 39 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.74% | — | — | |
| 40 | AXSM | Axsome Therapeutics INC | Stock-Healthcare | 0.74% | — | -15.49% | |
| 41 | QURE | uniQure N.V. | Stock-Other | 0.72% | +0.33% | +189.69% | |
| 42 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 0.70% | — | -26.03% | |
| 43 | ELV | Elevance Health INC | Stock-Healthcare | 0.69% | — | +15.74% | |
| 44 | RLMD | Relmada Therapeutics INC | Stock-Other | 0.67% | +0.39% | +80.64% | |
| 45 | FBRX | Forte Biosciences INC | Stock-Other | 0.64% | — | — | |
| 46 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.60% | — | -23.08% | |
| 47 | ESPR | Esperion Therapeutics INC | Stock-Other | 0.59% | — | +77.19% | |
| 48 | NPCE | Neuropace INC | Stock-Other | 0.57% | — | -12.87% | |
| 49 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 0.56% | — | +30.98% | |
| 50 | PVLA | Palvella Therapeutics INC | Stock-Other | 0.47% | +0.46% | NEW |
Performance for Q3 2026
+15%
Performance Last 4 Quarters
+50.8%
Based on 71% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings | |
|---|---|---|---|---|---|
| 2026 Q1 | 114 | $5.0B | 64 | ||
| 2025 Q4 | 108 | $4.9B | 37 | ||
| 2025 Q3 | 110 | $4.3B | 66 | ||
| 2025 Q2 | 103 | $4.0B | 0 | ||
| 2025 Q1 | 111 | $4.2B | 100 | ||
| 2024 Q4 | 119 | $4.9B | 0 | ||
| 2024 Q3 | 119 | $5.5B | 0 | ||
| 2024 Q2 | 115 | $5.1B | 0 | ||
| 2024 Q1 | 115 | $5.5B | 0 | ||
| 2023 Q4 | 111 | $5.0B | 0 | ||
| 2023 Q3 | 128 | $4.7B | 0 | ||
| 2023 Q2 | 127 | $5.5B | 0 | ||
| 2023 Q1 | 125 | $5.1B | 0 | ||
| 2022 Q4 | 116 | $5.2B | 0 | ||
| 2022 Q3 | 132 | $5.4B | 0 | ||
| 2022 Q2 | 145 | $5.5B | 0 | ||
| 2022 Q1 | 145 | $6.2B | 0 | ||
| 2021 Q4 | 159 | $7.8B | 0 | ||
| 2021 Q3 | 173 | $9.1B | 0 | ||
| 2021 Q2 | 160 | $9.9B | 31 | ||
| 2021 Q1 | 159 | $10.7B | 55 | ||
| 2020 Q4 | 149 | $11.4B | 53 | ||
| 2020 Q3 | 143 | $8.0B | 48 | ||
| 2020 Q2 | 135 | $7.1B | 48 | ||
| 2020 Q1 | 142 | $6.0B | 61 | ||
| 2019 Q4 | 136 | $7.0B | 52 | ||
| 2019 Q3 | 116 | $5.3B | 41 | ||
| 2019 Q2 | 128 | $6.5B | 40 | ||
| 2019 Q1 | 124 | $6.5B | 58 | ||
| 2018 Q4 | 131 | $5.4B | 59 | ||
| 2018 Q3 | 150 | $8.3B | 33 | ||
| 2018 Q2 | 147 | $8.4B | 41 | ||
| 2018 Q1 | 141 | $8.1B | 48 | ||
| 2017 Q4 | 133 | $7.9B | 41 | ||
| 2017 Q3 | 143 | $10.5B | 27 | ||
| 2017 Q2 | 138 | $9.5B | 36 | ||
| 2017 Q1 | 136 | $8.8B | 29 | ||
| 2016 Q4 | 132 | $7.8B | 38 | ||
| 2016 Q3 | 140 | $8.8B | 43 | ||
| 2016 Q2 | 137 | $9.6B | 30 | ||
| 2016 Q1 | 141 | $9.5B | 33 | ||
| 2015 Q4 | 130 | $11.0B | 32 | ||
| 2015 Q3 | 132 | $9.9B | 100 | ||
| 2015 Q2 | 136 | $12.0B | 0 | ||
| 2015 Q1 | 135 | $11.7B | 35 | ||
| 2014 Q4 | 131 | $10.5B | 31 | ||
| 2014 Q3 | 130 | $9.6B | 41 | ||
| 2014 Q2 | 132 | $8.5B | 26 | ||
| 2014 Q1 | 140 | $8.1B | 41 | ||
| 2013 Q4 | 120 | $6.8B | 52 | ||
| 2013 Q3 | 127 | $5.6B | 40 | ||
| 2013 Q2 | 127 | $4.7B | 0 |
Orbimed Advisors LLC's most significant position changes for 2026-03-31: New buy: Mdxhealth SA; New buy: Avita Medical INC (RCEL); New buy: AstraZeneca PLC (AZN); New buy: Myriad Genetics INC (MYGN); Sold out: Terns Pharmaceuticals INC (430).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ELVN | Enliven Therapeutics INC | +3.7% | — | Unchanged |
| 2 | EWTX | Edgewise Therapeutics INC | +1.8% | — | Unchanged |
| 3 | CRVS | Corvus Pharmaceuticals INC | +1% | — | Unchanged |
| 4 | XENE | Xenon Pharmaceuticals INC | +0.8% | +137.02% | Add |
| 5 | PRAX | Praxis Precision Medicines I | +0.5% | +82.54% | Add |
| 6 | RLMD | Relmada Therapeutics INC | +0.4% | +80.64% | Add |
| 7 | MLYS | Mineralys Therapeutics INC | +0.4% | +109.39% | Add |
| 8 | STTK | Shattuck Labs INC | +0.3% | — | Unchanged |
| 9 | QURE | uniQure N.V. | +0.3% | +189.69% | Add |
| 10 | AVTX | Avalo Therapeutics INC | -0.3% | -59.98% | Trim |
| 11 | ✓ | Adc Therapeutics SA | -0.3% | -77.36% | Trim |
| 12 | IRON | Disc Medicine INC | -0.4% | — | Unchanged |
| 13 | MBX | Mbx Biosciences INC | -0.4% | -7.56% | Trim |
| 14 | DHR | Danaher CORP | -0.4% | -11.34% | Trim |
| 15 | ARGX | Argenx Se - Adr | -0.5% | -6.23% | Trim |
| 16 | EYPT | Eyepoint INC | -0.7% | -56.69% | Trim |
| 17 | SPRY | Ars Pharmaceuticals INC | -0.7% | — | Unchanged |
| 18 | NTRA | Natera INC | -0.7% | -28.38% | Trim |
| 19 | CAI | Caris Life Sciences INC | -0.7% | -9.92% | Trim |
| 20 | ISRG | Intuitive Surgical INC | -1.1% | -20.77% | Trim |
| 21 | SYK | Stryker CORP | -1.1% | -43.85% | Trim |
| 22 | EW | Edwards Lifesciences CORP | -1.5% | -38.25% | Trim |
| 23 | ALNY | Alnylam Pharmaceuticals INC | -1.6% | -58.80% | Trim |
| 24 | BSX | Boston Scientific CORP | -1.8% | -1.54% | Trim |
| 25 | UPB | Upstream Bio INC | -2.1% | — | Unchanged |
| 26 | LLY | Eli Lilly & Co | -2.3% | -21.38% | Trim |
| 27 | ✓ | Mdxhealth SA | — | NEW | New buy |
| 28 | RCEL | Avita Medical INC | — | NEW | New buy |
| 29 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 30 | MYGN | Myriad Genetics INC | — | NEW | New buy |
| 31 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 32 | MRK | Merck & Co. INC. | — | NEW | New buy |
| 33 | APLSUSD | Apellis Pharmaceuticals INC | — | EXIT | Sold out |
| 34 | CI | THE Cigna Group | — | EXIT | Sold out |
| 35 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 36 | UTHR | United Therapeutics CORP | — | EXIT | Sold out |
| 37 | ROIV | Roivant Sciences Ltd. | — | EXIT | Sold out |
| 38 | RNAGBP | Avidity Biosciences INC | — | EXIT | Sold out |
| 39 | NBIX | Neurocrine Biosciences INC | — | EXIT | Sold out |
| 40 | GH | Guardant Health INC | — | NEW | New buy |
| 41 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 42 | BRKR | Bruker CORP | — | EXIT | Sold out |
| 43 | PVLA | Palvella Therapeutics INC | — | NEW | New buy |
| 44 | SNDX | Syndax Pharmaceuticals INC | — | NEW | New buy |
| 45 | STRO | Sutro Biopharma INC | — | NEW | New buy |
| 46 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 47 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 48 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 49 | CTMX | Cytomx Therapeutics INC | — | EXIT | Sold out |
| 50 | VIR | Vir Biotechnology INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026 Q1 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025 Q4 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025 Q3 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025 Q2 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025 Q1 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024 Q4 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024 Q3 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024 Q2 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024 Q1 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023 Q4 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023 Q3 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023 Q2 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023 Q1 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022 Q4 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022 Q3 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022 Q2 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022 Q1 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021 Q4 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021 Q3 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021 Q2 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021 Q1 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020 Q4 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020 Q3 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020 Q2 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020 Q1 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019 Q4 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019 Q3 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019 Q2 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019 Q1 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018 Q4 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018 Q3 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018 Q2 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018 Q1 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017 Q4 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017 Q3 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017 Q2 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017 Q1 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016 Q4 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016 Q3 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016 Q2 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016 Q1 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015 Q4 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015 Q3 | 2015-11-18 | Amendment | View on EDGAR |
| 2015 Q3 | 2015-11-13 | 13F-HR | View on EDGAR |
| 2015 Q2 | 2015-08-20 | Amendment | View on EDGAR |
| 2015 Q2 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015 Q1 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014 Q4 | 2015-02-13 | 13F-HR | View on EDGAR |
| 2014 Q3 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014 Q2 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014 Q1 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013 Q4 | 2014-02-14 | 13F-HR | View on EDGAR |
| 2013 Q3 | 2013-11-14 | 13F-HR | View on EDGAR |
| 2013 Q2 | 2013-08-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001379995
Total reported value
$5.0B
672 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0000728079
Total reported value
$5.0B
295 stks
2019-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001732768
Total reported value
$5.1B
35 stks
2026-03-31
AUM within 0.4% of this institution
Institutions with overlapping top holdings
CIK 0001388325
Total reported value
$1.2B
22 stks
2026-03-31
Also holds Edgewise Therapeutics INC as its largest position
CIK 0001631614
Total reported value
$43.0M
7 stks
2025-09-30
Stale — no recent filing
Also holds Edgewise Therapeutics INC as its largest position
Access Orbimed Advisors LLC's institutional profile programmatically:
REST API
curl https://alphasmo.com/api/v1/institutions/orbimed-advisors-llcCLI
npx alphasmo institutions get orbimed-advisors-llc